Rituximab-induced severe acute thrombocytopenia: a case report and review of literature.
Rituximab, an anti-CD20 monoclonal antibody, is generally a safe and well-tolerated drug. Severe acute thrombocytopenia following administration of rituximab is a rare phenomenon, with few previously reported cases in the literature. We report a case of an 84-year old male with a diagnosis of mantle cell lymphoma who suffered severe acute thrombocytopenia following rituximab infusion. A literature review of the previously published cases is also presented.
Dhand
Suneel
S
Franklin Square Hospital Center, Baltimore, Maryland 21237, USA. suneeldhand@hotmail.com
Bahrain
Huzefa
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D013921:Thrombocytopenia / Q000097:blood / Q000175:diagnosis* / Q000209:etiology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab